SCHEMBL4134057

SCHEMBL4134057

CCCC(C(=O)O)c1ccc(NC2=NC(=O)C(=Cc3ccc(-c4ccc(SCc5ccccc5)cc4)cc3)S2)cc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 4/20 0.37
MYC P01106 1/20 0.34
MAX P61244 1/20 0.34
CISD1 Q9NZ45 1/20 0.34
PTPN1 P18031 4/20 0.33
MAPT P10636 5/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
MITF O75030 3/20 0.33
HPGD P15428 3/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.32
HAO1 Q9UJM8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4134054 1.00 ALOX5 (0.37) ALOX5MYCMAXCISD1PTPN1
SCHEMBL4141057 0.82 PTPN1 (0.42) ALOX5MYCMAXCISD1PTPN1
SCHEMBL4141062 0.82 PTPN1 (0.42) ALOX5MYCMAXCISD1PTPN1
SCHEMBL4140448 0.79 ALOX5 (0.36) ALOX5PTPN1MAPTALDH1A1KDM4E
SCHEMBL4140451 0.79 ALOX5 (0.36) ALOX5PTPN1MAPTALDH1A1KDM4E
SCHEMBL4634855 0.77 ACKR3 (0.35) ALOX5CISD1PTPN1MEN1KMT2A
SCHEMBL4634853 0.77 ACKR3 (0.35) ALOX5CISD1PTPN1MEN1KMT2A
SCHEMBL4143594 0.76 MAOA (0.43) ALOX5CISD1
SCHEMBL4125487 0.76 ALOX5 (0.38) ALOX5CISD1MAPTALDH1A1MEN1
SCHEMBL4125493 0.76 ALOX5 (0.38) ALOX5CISD1MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885MYC 2793/4885MAX 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.